JoyceFuLiuMD

Oncology • Charlestown, MA

Instructor in Medicine, Dana-Farber Cancer Institute

Join to view full profile

Dr. Liu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Liu's full profile

Already have an account?

Office
55 Fruit Street Yawkey 7604
Mass General Physician Organization
Charlestown, MA 02129
Phone+1 617-726-2782

Fax+1 617-726-2894

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2005 - 2008
Brigham and Women's HospitalResidency, Internal Medicine, 2002 - 2005
Harvard Medical SchoolClass of 2002

Certifications & Licensure

FL State Medical License 2022 - Present
VT State Medical License 2023 - 2026
MA State Medical License 2004 - 2025
NH State Medical License 2024 - 2024
American Board of Internal Medicine Medical Oncology

Clinical Trials

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Start of enrollment: 2010 Apr 14
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer Start of enrollment: 2011 Apr 01
Completed
Phase 2
A Study of BBI503 in Adult Patients With Advanced Solid Tumors Start of enrollment: 2012 Feb 01
Completed
Phase 1
AO-176 in Multiple Solid Tumor Malignancies Start of enrollment: 2019 Feb 04
Completed
Phase 1, Phase 2
AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma Start of enrollment: 2018 Oct 22
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Contact, Principal Investigator
Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2018 Dec 07
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Contact, Principal Investigator
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib Start of enrollment: 2016 Nov 10
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator
The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors Start of enrollment: 2021 Feb 25
Recruiting
Phase 1
Roles: Principal Investigator, Contact
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers Start of enrollment: 2023 Sep 14
RECRUITING
PHASE1
Roles: Principal Investigator, Contact
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 Start of enrollment: 2023 Nov 14
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator, Contact
Azenosertib in Uterine Serous Carcinoma: Biomarker Study Start of enrollment: 2025 Apr 01
RECRUITING
PHASE2
Roles: Sponsor-Investigator, Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Role of adjuvant radiotherapy modality on clinical outcomes for early-stage uterine carcinosarcoma.
Kevin Tyan, Kevin X Liu, Alicia C Smart, Colleen M Feltmate, Neil S Horowitz
Gynecologic Oncology. 2025-03-08
Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer o...
Ana C Garrido-Castro, Noah Graham, Lestat R Ali, Christina Herold, Jennifer Desrosiers
Journal for Immunotherapy of Cancer. 2025-02-25
PARG inhibitor sensitivity correlates with accumulation of single-stranded DNA gaps in preclinical models of ovarian cancer.
Ramya Ravindranathan, Ozge Somuncu, Alexandre André B A da Costa, Sirisha Mukkavalli, Benjamin P Lamarre
Proceedings of the National Academy of Sciences of the United States of America. 2024-11-19

Lectures

A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

Nivolumab/bevacizumab Combo Promising in Relapsed Ovarian CancerOctober 19th, 2019
OncLive® Presents Latest State of the Science Summit™ on Ovarian Cancer and STSNovember 29th, 2018
Update Sustains Olaparib/Cediranib PFS Benefit in Ovarian CancerJune 9th, 2017
Join now to see all

JoyceFuLiuMD

Dr. Liu is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Viewing the full profile is available to verified healthcare professionals only.